Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease

Bibliography

• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global Burden of Disease Study. Lancet 1997;349:1498-504
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-55
   PubMed Web of Science ®Google Scholar
• Peter MA, Calverley MD, et al. On behalf of the TORCH investigators. Salmeterol and fluticasone propionate and survival in Chronic Obstructive Pulmonary Disease. NEJM 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Spencer S, Karner C, Cates CJ, Evans DJ. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;12):CD007033
   Web of Science ®Google Scholar
• GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf [Last accessed 25 February 2013]
   Google Scholar
• Jones PW. St. George's respiratory questionnaire: MCID. COPD 2005;2(1):75-9
   PubMedGoogle Scholar
• Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnea at rest in COPD. Eur Respir J 2003;21:86-94
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. AdvairDiskus® 100/50, 250/50, 500/50 prescribing information [online]. Available from: www.gsk.com/products/advair [Last accessed 25 February 2013]
   Google Scholar
• Tay HL, Armoogum N, Tan LKS. Nasal mucociliary clearance and salmeterol. Clin Otolaryngol 1997;22:68-70
   PubMed Web of Science ®Google Scholar
• Kanthakumar K, Cundell DR, Johnson M, et al. Effect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotoxin, pyocyanin. Br J Pharmacol 1994;112:493-8
   PubMed Web of Science ®Google Scholar
• Piatti G, Ambrosetti U, Santus P, et al. Effects of salmeterol on cilia and mucus in COPD and pneumonia patients. Pharmacol Res 2005;51(2):165-8
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bailey WC. Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. Expert Opin Pharmacother 2004;5(8):1815-26
   PubMed Web of Science ®Google Scholar
• Cazzola M, Santangelo G, Piccolo A. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994;7:2-103-7
   Google Scholar
• Mollmann H, Wagner M, Krishnaswami S, et al. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol 2001;41:1329-38
   PubMed Web of Science ®Google Scholar
• Thorsson L, Edsbaäcker S, Källen A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®. Br J ClinPharmacol 2001;52:529-38
   PubMed Web of Science ®Google Scholar
• Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce beta-2 adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997;155(2):704-10
   PubMed Web of Science ®Google Scholar
• Kalavantavanich K, Schramm CM. Dexamethasone potentiates high-affinity binding and Gsalpha protein expression in airway smooth muscle. Am J Physiol Lung Cell MolPhysiol 2000;278(5):L1101-6
   Web of Science ®Google Scholar
• Mak JCW, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on downregulation of pulmonary beta-2 adrenergic receptors in vivo. J Clin Invest 1995;96:99-106
   PubMed Web of Science ®Google Scholar
• Eickelberg O, Roth M, Lörx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta-2 adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274(2):1005-10
   PubMed Web of Science ®Google Scholar
• Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005;172(6):704-12
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SFP. Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients? Curr Opin Pulm Med 2007;13(2):90-7
   PubMed Web of Science ®Google Scholar
• Barnes NC, Qiu Y-S, Pavord ID, et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173(7):736-43
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax 2007;62(11):938-43
   PubMed Web of Science ®Google Scholar
• Yang L, Qian-li M, Yao W, et al. Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4+CD25+Foxp3+ regulatory T cells in COPD. Respir Res 2011;12:142
   PubMed Web of Science ®Google Scholar
• Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170(7):760-5
   PubMed Web of Science ®Google Scholar
• Dalby C, Polanowski T, Larsson T, et al. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res 2009;10:104
   PubMed Web of Science ®Google Scholar
• AdvairDiskus. Highlights of prescribing information. Available from: http://us.gsk.com/products/assets/us_advair.pdf [Last accessed 10 April 2013]
   Google Scholar
• AdvairDiskus. Highlights of prescribing information. Available from: http://us.gsk.com/products/assets/us_advair_hfa.pdf [Last accessed 30 April 2013]
   Google Scholar
• Hagedorn C, Kässner F, Banik N, et al. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD. Respir Med 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-4
   PubMed Web of Science ®Google Scholar
• Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice. Eur Resp J 2002;20:1-7
   PubMed Web of Science ®Google Scholar
• Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003;2:1):67–74
   PubMedGoogle Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. for the TRISTAN (TRial of Inhaled STeroidsANd long-acting beta2 agonists study group. Lancet 2003;361:449-56
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178(4):332-8
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Shah M, D'Souza AO, et al. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respir Res 2012;13(1):15
   PubMed Web of Science ®Google Scholar
• Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 2012;106(3):382-9
   PubMed Web of Science ®Google Scholar
• Sin DD, Paul Man SF, Marciniuk DD, et al. The effects of Fluticasone with or without Salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:1207-14
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;9:CD006829
   PubMed Web of Science ®Google Scholar
• Aaron SD. Review: corticosteroid plus LABA inhalers, vs. LABAs alone, reduce morbidity in COPD. Ann Intern Med 2013;158(4):JC9
   PubMed Web of Science ®Google Scholar
• Mapel DW, Nelson LS, Lydick E, et al. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. JCOPD 2007;4:127-34
   Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007(4):CD003794
   Google Scholar
• Yawn BP, Raphiou I, Hurley JS, Dalal AA. The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2010;5:165-78
   PubMedGoogle Scholar
• Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175(2):144-9
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102(8):1099-108
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, PLA controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53
   PubMed Web of Science ®Google Scholar
• Johnell O, Pauwels R, Lofdahl CG, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002;19:1058-63
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009;136:1456-65
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-16
   PubMed Web of Science ®Google Scholar
• Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-29
   PubMed Web of Science ®Google Scholar
• Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011;139:505-12
   PubMed Web of Science ®Google Scholar
• Halpin DM, Gray J, Edwards SJ, et al. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J ClinPract 2011;65(7):764-74
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013;346:f3306
   PubMed Web of Science ®Google Scholar
• Suissa S. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 2013;68:540-3
   PubMed Web of Science ®Google Scholar
• Keene ON, Anzueto A, Ferguson GT, Calverley MA. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 2013;00:1; Correspondence
   Google Scholar
• Anzueto A, Ferguson GT, Fieldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6:320-9
   PubMedGoogle Scholar
• Fuso L, Mores N. Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Yawn BP, Li Y, Tian H, et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J COPD 2013;8:295-304
   Google Scholar
• Fahim A, Faruqi S, Wright CE, et al. Comparison of the effect of high-dose inhaled budesonide and fluticasone on adrenal function in patients with severe chronic obstructive pulmonary disease. Ann Thorac Med 2012;7(3):140-4
   PubMed Web of Science ®Google Scholar
• Glick H, Briggs A, Lozano-Ortega G, et al. Is treatment with ICS/LABA combination good value for money in COPD? Crit Care Med 2007;175(Suppl):A763
   Google Scholar
• Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment fluticasone propionate versus salmeterol on exacerbations in Pharmacoeconomics. 2005;23(6):619-37
   Google Scholar
• Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698-702
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56
   PubMed Web of Science ®Google Scholar
• Calverley PM, Spencer S, Willits L, et al. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003;124:1350-6
   PubMed Web of Science ®Google Scholar
• Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166(8):1084-91
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
   PubMed Web of Science ®Google Scholar
• van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002;166:1358-63
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23
   PubMed Web of Science ®Google Scholar
• Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD002991
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19
   PubMed Web of Science ®Google Scholar
• Mahler DA. Pulmonary rehabilitation. Chest 1998;113:263S-8S
   PubMed Web of Science ®Google Scholar
• Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasonefuroate/formoterolfumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate- to-very severe COPD. Int J Chron Obstruct Pulmon Dis 2012;7:57-71
   PubMed Web of Science ®Google Scholar
• Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-50
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with PLA, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Donohue JF, Mahler DA, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009;103:516-24
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009;6:17-25
   PubMedGoogle Scholar
• van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2006;26:214-22
   Web of Science ®Google Scholar
• Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67:781-8
   PubMed Web of Science ®Google Scholar
• D'Urzo A, Vogelmeier C. Future of chronic obstructive pulmonary disease management. Expert Rev Respir Med 2012;6:285-99
   PubMed Web of Science ®Google Scholar
• van Noord JA, Buhl R, Laforce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2012;65:1086-91
   Web of Science ®Google Scholar
• Van de MB, Fabbri LM, Martin C, et al. Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD 2010;7:418-27
   PubMedGoogle Scholar
• Banerji D, Chen H, Patalano F. The QVA149 IGNITE programme: dual bronchodilation as the future of COPD management. Prim Care Resp 2012;6:1022-7
   Google Scholar
• Wedzicha J, Decramer M, Ficker J, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209
   PubMed Web of Science ®Google Scholar
• Vogelmeir C, Bateman E, Pallante J, Bryant H. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol—fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1:51-60
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med 2013;107(4):550-9
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med 2013;107(4):560-9
   PubMed Web of Science ®Google Scholar